Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
LORIN
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
- NCT05740943 ↗
- Active, not recruiting
- Guangdong Provincial People's Hospital
- Deep
We haven't built an HCP commentary report on LORIN (lorlatinib in Stage III NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LORIN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 32 | |
| Podcasts | 3 | |
| YouTube | 2 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Induction Lorlatinib for ALK Fusion Locally Advanced Non-small Cell Lung Cancer: A Prospective, Single Arm, Open-label Phase 2 Study
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Stage III NSCLC; Surgery
- Interventions
- Lorlatinib
- Arms
- Treatment Arm · Experimental
- Enrollment
- 48 (estimated)
- Primary outcomes
- Pathological Complete Response (pCR)
- Sponsor
- Guangdong Provincial People's Hospital with Guangzhou No.12 People's Hospital, Peking Union Medical College Hospital, Second Xiangya Hospital of Central South University
- Start
- Mar 15, 2023
- Primary completion
- Dec 31, 2025
- Results posted
- No
- Registry record
- NCT05740943 · updated Jan 20, 2026
Publications
linked from the registry- Zhang C, Li SL, Nie Q, Dong S, Shao Y, Yang XN, Wu YL, Yang Y, Zhong WZ. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement. J Thorac Oncol. 2019 Apr;14(4):726-731. doi: 10.1016/j.jtho.2018.10.161. Epub 2018 Nov 5. PubMed 30408570
- Leonetti A, Minari R, Boni L, Gnetti L, Verze M, Ventura L, Musini L, Tognetto M, Tiseo M. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. Clin Lung Cancer. 2021 Sep;22(5):473-477. doi: 10.1016/j.cllc.2021.02.014. Epub 2021 Feb 24. PubMed 33762169
- Zhang C, Yan LX, Jiang BY, Wu YL, Zhong WZ. Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC. J Thorac Oncol. 2020 Jun;15(6):e95-e99. doi: 10.1016/j.jtho.2019.12.133. No abstract available. PubMed 32471573
- Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT, Gainor JF. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer. 2018 Aug;122:67-71. doi: 10.1016/j.lungcan.2018.05.020. Epub 2018 May 22. PubMed 30032847
- Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. PubMed 33207094